Packages (Simulation)
Image (I)
-
IHC Images
-
IHC Image
-
IHC Image
-
IHC Image
-
IHC Image
Image (II)
-
Figure. Western Blot; Sample: Recombinant VEGFC, Mouse.
-
Figure. Western Blot; Sample. Lane1: Mouse Brain Tissue; Lane2: Mouse Breast Tissue.
Quality Guarantee
Instruction Manual
Certificate
Polyclonal Antibody to Vascular Endothelial Growth Factor C (VEGFC)
VEGF-C; Flt4-L; VRPL; Vascular Endothelial Growth Factor-Related Protein
- Product No.PAA145Mu01
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- SourcePolyclonal antibody preparation
- HostRabbit
- Potencyn/a
- Ig Type IgG
- PurificationAntigen-specific affinity chromatography followed by Protein A affinity chromatography
- LabelNone
- Immunogen RPA145Mu01-Recombinant Vascular Endothelial Growth Factor C (VEGFC)
- Buffer FormulationPBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
- TraitsLiquid
- Concentration0.5mg/ml
- Organism Species MoreHomo sapiens (Human), Rattus norvegicus (Rat)
- ApplicationsWB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies. - DownloadInstruction Manual
- UOM 20µl100µl 200µl 1ml 10ml
- FOB
US$ 97
US$ 227
US$ 324
US$ 810
US$ 3240
For more details, please contact local distributors!
SPECIFITY
The antibody is a rabbit polyclonal antibody raised against VEGFC. It has been selected for its ability to recognize VEGFC in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.01-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
GIVEAWAYS
INCREMENT SERVICES
-
Antibody Labeling Customized Service
-
Protein A/G Purification Column
-
Staining Solution for Cells and Tissue
-
Positive Control for Antibody
-
Tissue/Sections Customized Service
-
Phosphorylated Antibody Customized Service
-
Western Blot (WB) Experiment Service
-
Immunohistochemistry (IHC) Experiment Service
-
Immunocytochemistry (ICC) Experiment Service
-
Flow Cytometry (FCM) Experiment Service
-
Immunoprecipitation (IP) Experiment Service
-
Immunofluorescence (IF) Experiment Service
-
Buffer
-
DAB Chromogen Kit
-
SABC Kit
-
Long-arm Biotin Labeling Kit
-
Real Time PCR Experimental Service
| Magazine | Citations |
| Journal of Cellular Biochemistry | Alternatively activated RAW264. 7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinoma PubMed: 19241443 |
| genetics and molecular research | Expression of COX-2 and VEGF-C in cholangiocarcinomas at different clinical and pathological stages PubMed: 26125824 |
| Experimental and Therapeutic | Fenofibrate inhibits the expression of VEGFC and VEGFR-3 in retinal pigmental epithelial cells exposed to hypoxia PubMed: 26622498 |
| Am J Pathol | IL-10 Indirectly Regulates Corneal Lymphangiogenesis and Resolution of Inflammation via Macrophages PubMed: 26608451 |
| PLoS One. | Interleukin-6 Induces Vascular Endothelial Growth Factor-C Expression via Src-FAK-STAT3 Signaling in Lymphatic Endothelial Cells. pubmed:27383632 |
| Oncology Letters | RNAi-mediated gene silencing of vascular endothelial growth factor C suppresses growth andinduces apoptosis in mouse breast cancer in vitro and in vivo. pubmed:27895746 |
| Angiogenesis | Characterization of isolated liver sinusoidal endothelial cells for liver bioengineering Pubmed:29582235 |
| Oncology Reports | Effects of diphyllin as a novel V-ATPase inhibitor on TE-1 and ECA-109 cells Pubmed:29328465 |
| LABORATORY INVESTIGATION | Dynamic signature of lymphangiogenesis during acute kidney injury and chronic kidney disease Pubmed: 31019289 |
| Cutaneous and Ocular Toxicology | Isotretinoin does not alter VEGF-A and VEGF-C levels: Do retinoids behave differently in dose-dependent and/or in vivo/in vitro conditions? Pubmed: 32722957 |